Irinotecan Accord

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinotecan Accord, is a topoisomerase I inhibitor presented as an intravenous infusion for intravenous use. It is employed in the treatment of metastatic colorectal cancer and other solid tumours in adult patients. It is indicated for adult patients with advanced disease who have progressed after standard therapies.

GNH USA supplies Irinotecan Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across all shipments.

Irinotecan is a topoisomerase I inhibitor used in chemotherapy regimens for colorectal and other solid tumours.

Metastatic colorectal cancer: provides systemic chemotherapy to shrink tumors and improve survival. Adjuvant colorectal cancer: administered after surgery to reduce the risk of disease recurrence. Other solid tumours: employed in selected cases of gastric, pancreatic or lung cancers when standard options are exhausted.

Irinotecan may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Diarrhea - Neutropenia - Fatigue

Serious or Rare Side Effects: - Febrile neutropenia (severe neutropenia with fever) - Life‑threatening colitis (severe diarrhea) - Cholinergic syndrome (abdominal cramping, sweating, lacrimation) - Hepatic toxicity (elevated liver enzymes)

When using Irinotecan, clinicians should observe several safety measures to minimise risks. - Monitor blood counts: perform regular CBC to detect neutropenia early. - Assess liver function: adjust dose in hepatic impairment. - Ensure adequate hydration: reduce severity of diarrhea and renal complications. - Avoid strong CYP3A4 inhibitors: may increase SN‑38 exposure and toxicity. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks, as safety data are lacking. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Irinotecan interacts with several drugs that can alter its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase SN‑38 levels. - UGT1A1 inhibitors (e.g., atazanavir): raise risk of severe neutropenia. - Concurrent myelosuppressive chemotherapy: additive bone‑marrow toxicity.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin): enhanced bleeding risk due to liver enzyme changes. - Anticholinergic agents: may exacerbate cholinergic syndrome. - Diuretics: can worsen electrolyte imbalances during diarrhea.